Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503174 · ClinicalTrials.gov registry record
Control-IQ Observational (CLIO) Post-Approval Study
A clinical trial, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- 3,157
- Enrollment target
NCT04503174 is a clinical trial that has completed, run by Tandem Diabetes Care. The registered enrollment target is 3,157 participants.
The verdict
NCT04503174 has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- 3,157 participants
- Enrollment target
Study Summary
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
Interventions
- DEVICE t:slim X2 pump with Control-IQ technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,157 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2023-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04503174
The ClinicalTrials.gov registry entry for NCT04503174 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tandem Diabetes Care, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which t:slim X2 pump with Control-IQ technology is the first listed.
NCT04503174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04503174 about?
NCT04503174 is a clinical study titled "Control-IQ Observational (CLIO) Post-Approval Study". Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
What is the current status of trial NCT04503174?
This trial is currently completed. The enrollment target is 3,157 participants. The study started on 2020-08-04. Estimated completion is 2023-06-26.
What interventions are being tested in trial NCT04503174?
The interventions under investigation include: t:slim X2 pump with Control-IQ technology (DEVICE).
Who is sponsoring clinical trial NCT04503174?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.